Helen I. Torley
2014
In 2014, Helen I. Torley earned a total compensation of $10.4M as President and Chief Executive Officer at Halozyme Therapeutics.
Compensation breakdown
Bonus | $1,000,000 |
---|---|
Non-Equity Incentive Plan | $382,500 |
Option Awards | $6,437,200 |
Salary | $593,391 |
Stock Awards | $1,759,200 |
Other | $227,875 |
Total | $10,400,166 |
Torley received $6.4M in option awards, accounting for 62% of the total pay in 2014.
Torley also received $1M in bonus, $382.5K in non-equity incentive plan, $593.4K in salary, $1.8M in stock awards and $227.9K in other compensation.
Rankings
In 2014, Helen I. Torley's compensation ranked 481st out of 13,032 executives tracked by ExecPay. In other words, Torley earned more than 96.3% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 481 out of 13,032 | 96th |
Division Manufacturing | 163 out of 4,966 | 97th |
Major group Chemicals And Allied Products | 52 out of 1,686 | 97th |
Industry group Drugs | 42 out of 1,365 | 97th |
Industry Biological Products, Except Diagnostic Substances | 3 out of 236 | 99th |
Source: SEC filing on March 24, 2017.
Torley's colleagues
We found four more compensation records of executives who worked with Helen I. Torley at Halozyme Therapeutics in 2014.
News
Halozyme Therapeutics CEO Helen Torley's 2021 pay rises 14% to $7.5M
March 25, 2022
Halozyme Therapeutics CEO Helen Torley's 2020 pay rises 11% to $6.5M
March 26, 2021
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019